Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

2014 ASH Annual Meeting

Hagop Kantarjian, MD, of The University of Texas MD Anderson Cancer Center, offers his thoughts on abstract 797, “First Results of the Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia Patients,” presented by Sabina Chiaretti, MD, PhD, and abstract 798, “Nilotinib and Chemotherapy for First-Line Treatment in Elderly Patients with De Novo Philadelphia Chromosome/BCR-ABL1–Positive Acute Lymphoblastic Leukemia (ALL): A Trial of the European Working Group for Adult ALL (EWALL-PH-02),” presented by Oliver G. Ottman, MD.

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, and Richard M. Stone, MD of the Dana-Farber Cancer Institute, discuss three clinical trials: different doses of daunorubicin for AML; comparing azacitidine plus lenolidomide to vorinostat vs azacitidine monotherapy in MDS and CMML; and sorafenib vs placebo in addition to standard treatment for AML.

Myelodysplastic Syndromes

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, of Moffitt Cancer Center and the University of South Florida, and James O. Armitage, MD, FACP, FRCP, of the University of Nebraska Medical Center, discuss the biology and diagnostic criteria for myelodysplastic syndrome, as well as advances in the disease presented at the 56th ASH Annual Meeting.

Myelodysplastic Syndromes

Leukemia

Alan F. List, MD

Apr

Today In Oncology

Hagop Kantarjian, MD, on Treating Philadelphia Chromosome–Positive ALL

Related Videos

James O. Armitage, MD, FACP, FRCP, and Richard M. Stone, MD, on Clinical Trial Results for AML, MDS, and CMML Treatment

Alan F. List, MD, and James O. Armitage, MD, FACP, FRCP, on Advances in Myelodysplastic Syndrome

Alan F. List, MD, on Sotatercept in Lower-Risk Myelodysplastic Syndromes

Richard M. Stone, MD, on the SAL-SORAML Trial

Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being

FDA Approves Lu-177 Dotatate for Pediatric Patients With GEP-NETs